Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dalfampridine
Drug ID BADD_D00574
Description Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Indications and Usage Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS).
Marketing Status approved
ATC Code N07XX07
DrugBank ID DB06637
KEGG ID D04127
MeSH ID D015761
PubChem ID 1727
TTD Drug ID D08YIN
NDC Product Code 10144-427; 63190-0510; 67877-444; 56125-427; 0591-2533; 65862-917; 62756-429; 63629-9450; 65862-863; 38779-3205; 42571-338; 51927-5030; 42571-275; 0378-4504; 12817-054; 46016-5042; 54382-125; 62756-038; 62991-3143; 65372-1157; 16729-292; 63190-0530; 51407-246; 0054-0479
UNII BH3B64OKL9
Synonyms 4-Aminopyridine | 4 Aminopyridine | Dalfampridine | Pymadine | VMI-103 | VMI 103 | VMI103 | 4-Aminopyridine Sustained Release | 4 Aminopyridine Sustained Release | Sustained Release, 4-Aminopyridine | Fampridine-SR | Fampridine SR
Chemical Information
Molecular Formula C5H6N2
CAS Registry Number 504-24-5
SMILES C1=CN=CC=C1N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nervousness19.06.02.0030.005114%Not Available
Neuralgia17.02.07.0050.003284%
Neurogenic bladder20.03.03.001; 17.10.01.0020.006191%Not Available
Night sweats23.02.03.006; 08.01.03.0310.003015%Not Available
Nocturia20.02.03.0010.001830%Not Available
Non-Hodgkin's lymphoma01.17.01.001; 16.35.01.0010.000538%Not Available
Nystagmus17.02.02.006; 06.05.02.0060.000538%
Oesophagitis07.08.05.0010.000538%
Optic neuritis10.02.01.097; 17.04.05.001; 06.04.08.0020.001454%Not Available
Osteoarthritis15.01.04.0010.001723%Not Available
Osteoporosis15.02.03.002; 14.04.04.0020.002369%
Pain in extremity15.03.04.0100.041399%
Panic attack19.06.04.0010.001077%Not Available
Paraesthesia23.03.03.094; 17.02.06.0050.043175%
Paralysis17.01.04.0040.000808%Not Available
Peripheral coldness23.06.04.008; 24.04.03.006; 08.01.09.0100.001184%Not Available
Peroneal nerve palsy17.09.02.0030.006945%Not Available
Personality change17.02.05.019; 19.05.01.0060.000538%
Petit mal epilepsy17.12.04.0010.000538%Not Available
Pharyngeal oedema23.04.01.016; 22.04.05.003; 10.01.05.0160.001454%Not Available
Photophobia17.17.02.006; 06.01.01.0040.001830%
Platelet disorder01.08.03.0010.001830%Not Available
Pollakiuria20.02.02.0070.023849%
Polyuria20.02.03.0020.003661%Not Available
Posture abnormal15.03.05.029; 17.02.05.0330.002746%Not Available
Pregnancy18.08.02.0040.002746%Not Available
Presyncope02.11.04.013; 24.06.02.010; 17.02.05.0090.002907%
Productive cough22.02.03.0050.003015%
Psychomotor hyperactivity19.11.02.003; 17.01.02.0110.003930%Not Available
Pulmonary congestion24.03.08.001; 22.01.03.002; 02.05.02.0020.001184%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 9 Pages